ATRA Atara Biotherapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
18:05
Jan 06
Jan 06
High-risk short into Jan 10 PDUFA after CRL.
The author argues ATRA is a high-risk short play into the Jan 10 PDUFA for its allogeneic T-cell immunotherapy for Epstein-Barr virus. They note the company received a CRL last year due to third-party CMC issues, with no clinical or efficacy issues mentioned, and see today's 12% drop as a good dip for the short. The post labels the position short play, high risk.
MED
About ATRA Investor Commentary
Across the available history and selected sources, Buzzberg tracks ATRA (Atara Biotherapeutics, Inc.) across 1 sources: 0 bullish vs 1 bearish calls from 1 authors. Historical directional balance: -100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Dry-Loss-5102.